Showing results (321-330 of 331) with videos related to

Sort By:
Pageof 34
Cell|November 16, 2019
Atoms to Phenotypes: Molecular Design Principles of Cellular Energy MetabolismAbhishek Singharoy, Christopher Maffeo, Karelia H Delgado-Magnero, et al.
The British Journal of Surgery|November 6, 2023
Mastitis and Mammary Abscess Management Audit (MAMMA) in the UK and IrelandAlona Courtney, Jonathon Clymo, Ruth Parks, et al.
Nature Medicine|January 21, 2014
The ryanodine receptor store-sensing gate controls Ca2+ waves and Ca2+-triggered arrhythmiasWenqian Chen, Ruiwu Wang, Biyi Chen, et al.
Nature Methods|March 30, 2021
Martini 3: a general purpose force field for coarse-grained molecular dynamicsPaulo C T Souza, Riccardo Alessandri, Jonathan Barnoud, et al.
European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [Et Al] = Zeitschrift Fur Kinderchirurgie|December 28, 2020
Does Use of a Feeding Protocol Change Outcomes in Gastroschisis? A Report from the Midwest Pediatric Surgery ConsortiumCharlene Dekonenko, Jason D Fraser, Katherine Deans, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TBSimon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
Molecular Cell|April 10, 2025
MLKL activity requires a splicing-regulated, druggable intramolecular interactionUris Ros, Veronica Martinez-Osorio, Pedro A Valiente, et al.
ACS Central Science|September 29, 2025
The Martini 3 Lipidome: Expanded and Refined Parameters Improve Lipid Phase BehaviorKasper B Pedersen, Helgi I Ingólfsson, Daniel P Ramirez-Echemendia, et al.
Pageof 34